Insights Into Multiple Myeloma (MM) 2021
Perspectives on current treatment practices regarding frontline therapy of multiple myeloma (MM), the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents
Southwest – February 23, 2021
Faculty Chair
Rafael Fonseca, MD
Mayo Clinic, Phoenix, AZ
Northwest – November 9, 2021
Faculty Chair
Nina Shah, MD
UCSF Health, San Francisco, CA
ASH Edition – December 20, 2021
Faculty Chair
Sagar Lonial, MD
Emory University, Georgia
More Information
- Virtual Series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- California, Nevada
More Information
- Virtual Series
- ASH Edition
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of multiple myeloma
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
